Bristol-Myers Squibb

Sanofi restructues cutting sales jobs

Wednesday, November 2, 2011 01:43 PM

French drugmaker Sanofi has reported it is reorganizing research operations in the U.S. and planning to trim its sales force for the second time in barely a year as it aims to boost efficiency, according to the Associated Press.

More... »

Bristol-Myers, Gilead ink licensing agreement for HIV medicines

Thursday, October 27, 2011 12:41 PM

Bristol-Myers Squibb and Gilead Sciences have signed a licensing agreement for Bristol-Myers Squibb to develop and commercialize a fixed-dose combination containing Bristol-Myers Squibb's protease inhibitor REYATAZ (atazanavir sulfate) and Gilead's cobicistat, a pharmacoenhancing or "boosting" agent that increases blood levels of certain HIV medicines to potentially allow for one pill once daily dosing. Gilead is currently studying atazanavir and cobicistat in phase II and III studies in HIV-1 treatment-naive patients.

More... »

Amgen names executive VP

Wednesday, October 19, 2011 01:50 PM

Amgen has named Anthony (Tony) Hooper, executive vice president, global commercial operations, effective October 26th. In this role, Hooper will report to Robert A. Bradway, president and chief operating officer.

More... »

Icon CEO Peter Gray to step down after nine years; CFO Ciaran Murray takes the helm as of Oct. 1

Monday, September 12, 2011 08:02 AM

Peter Gray, CEO of Icon since 2002, will step down as of Oct. 1. The announcement, which came last week, surprised many in the industry.  Icon’s board has appointed Ciaran Murray, who has been Icon’s CFO for the last six years, to succeed Gray as CEO.

More... »

Icon and Bristol-Myers Squibb build on strategic partnership, extending it to early-phase work

Monday, September 5, 2011 08:00 AM

Icon and Bristol-Myers Squibb (BMS) have inked a preferred-provider agreement for early-phase development. This constitutes the CRO’s second sizable agreement with BMS; in June 2010, the two formed a strategic partnership, with Icon focused on providing global support for the drug developer’s clinical development pipeline.

More... »

GNS constructs immuno-inflammation model with BMS trial data

Wednesday, August 17, 2011 10:17 AM

A computer model that can support virtual clinical trials in the field of immuno-inflammation is the goal of a new collaboration between Bristol-Myers Squibb (BMS) and US-based healthcare analytics company GNS Healthcare, according to PharmaTimes.

More... »

GNS, Bristol-Myers Squibb collaborate

Wednesday, August 10, 2011 12:14 PM

GNS Healthcare, a healthcare analytics company focused on enabling personalized medicine to improve human health, has entered into a collaboration with Bristol-Myers Squibb focused on the discovery of novel disease biology and biomarkers in the area of immuno-inflammation. Utilizing its supercomputer-driven REFS (reverse-engineering and forward-simulation) platform, GNS will use clinical and molecular information from a Bristol-Myers Squibb clinical trial to build computer models in a hypothesis-free, unbiased manner that will be simulated to identify key molecular mechanisms.

More... »

Tornoe joins Exagen Diagnostics

Wednesday, August 10, 2011 11:09 AM

Exagen Diagnostics has named Eric Tornoe its president and chief operating officer.

More... »

BMS acquires Amira for $325 million

Monday, July 25, 2011 10:11 AM

Bristol-Myers Squibb will acquire privately-held Amira Pharmaceuticals, a small-molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory and fibrotic diseases.

More... »

Icon acquires Firecrest Clinical, adding portal technology to boost site quality while reducing errors and costs

Monday, July 25, 2011 08:02 AM

As large pharmaceutical companies scrutinize the pack of mid- and top-tier CROs to determine who wins the coveted strategic-partnership agreements, there’s a mad scramble among CROs to differentiate themselves from one another and stand out as efficient, high quality, exciting and deserving.

More... »